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Objective: This systematic review aims to review the evidence for the diagnostic 
accuracy of the non-English updated versions of Addenbrooke’s Cognitive Examination 
(ACE)—the ACE-Revised (ACE-R) and the ACE-III—in the diagnosis of dementia. 
Methods:  A systematic search resulted in 16 eligible studies evaluating the diagnostic 
accuracy of ACE-R and ACE-III in ten different languages. Most studies were assessed 
as of medium to low quality using Standards For Reporting of Diagnostic Accuracy 
(STARD) guidance. Results: The findings of excellent diagnostic accuracy are 
compromised by the methodological limitations of studies. While studies generally 
reported excellent diagnostic accuracy across and within different languages, optimal 
cut-offs even within particular language versions, varied. Conclusion: There is a need 
for future research to address these limitations through adherence to STARD guidelines. 
The ACE-III is particularly under-evaluated and should be a focus of future research. 
The variance in obtained optimal cut-offs within language versions is an issue 
compromising clinical utility and could be addressed in future work through use of a-
priori defined thresholds. 
 





An accurate clinical diagnosis of dementia at an early stage and an early intervention 
that slows the progression of the disease can lead to a better prognosis (NICE, 2006). 
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Good quality screening tools with high sensitivity and specificity can facilitate this 
process (Prince, Renata & Ferri, 2011).  
The Addenbrooke’s Cognitive examination-revised (ACE-R) (Mioshi, Dawson, Mitchell, 
Arnold & Hodges, 2006) and the Addenbrooke’s Cognitive Examination III (ACE-III) 
(Hsieh, Schubert, Hoon, Mioshi & Hodges, 2013) are two brief (15-minute) screening tools 
that have been developed to screen for dementia (Velayudhan et al., 2014). Both tools 
provide sub-scale scores for the cognitive domains of attention and orientation, 
memory, language, visuospatial functioning and verbal fluency. The English versions of 
these tools have high diagnostic accuracy at the recommended cut-off of 88; the ACE-R 
has a sensitivity of 91.8% and specificity of 87.5% (Mioshi et al., 2006) and the ACE-
III has a sensitivity of 1 and specificity, 0.96 (Hsieh et al., 2013). The ACE-III was 
developed following potential licensing issues with the ACE-R, and is a very similar 
tool, they differ only in minor ways and in studies examining them together, scores have 
an almost perfect correlation (r = 0.99) (Hsieh et al., 2013). Thus while the authors have 
suggested that the ACE-III be used instead (Hsieh et al., 2013), results are likely to be 
very similar to those of the ACE-III, and will help inform future practice with this tool. 
Furthermore, as the ACE-R has been validated in more languages than the ACE-III, it 
may still have utility in assessing those with dementia who present to services who do 
not speak English fluently, despite the potential licensing issues. In support of this 
approach a number of studies validating the ACE-R in different languages have been 
published since the licensing issues arose (Fang et al., 2014; Sobreira et al., 2015; 
Gonçalves et al., 2015). Since the advent of the ACE-R and ACE-III, a number of non-
English language versions have been developed. This is important in widening access to 
dementia diagnosis and hence care in countries where English is the majority languages 
but have significant non-English speaking minorities such as the UK, Australia and 
USA (Grypma, Mahajani & Tam, 2007). It is also important in increasing access to 
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dementia care in countries where dementia prevalence is increasing and non-English 
language speakers may be in the majority (Alexopoulos et al., 2010). It is not possible 
to use the cut-off thresholds and diagnostic accuracy metrics of the English versions for 
non-English versions as the equivalence on these aspects of screening tools across 
cultures and language cannot be assumed (Borsa, Damasio & Bandeira, 2012). 
Consequently, the aim of the current paper is to review the evidence as to the diagnostic 
accuracy of the non-English versions of the ACE-R and the ACE-III in diagnosing 
dementia with reference to diagnostic accuracy metrics derived from receiver operating 
characteristic (ROC) analysis as recommended in the Standards for Reporting of 
Diagnostic Accuracy (STARD) (Bossuyt et al., 2015). Despite the licensing issues, the 
majority of the published non-English versions of this measure is on ACE-R. Therefore, 
a secondary aim of this review is to shade the light on common methodological 
problems in the non-English versions of ACE-R to be considered in future translations 




A systematic search and appraisal (using STARD guidelines) of published evidence on 
the diagnostic accuracy of non-English language versions of the ACE-R and ACE-III 
was undertaken.  The search and appraisal were in line with systematic principles 
(Moher, Liberati, Tetzlaff  & Altman, 2009). 
Search Strategy 
Three electronic databases were searched: PsychINFO, MEDLINE, and EMBASE. The 
following search words were used: Addenbrooke’s Cognitive Examination-Revised, 
Addenbrooke’s Cognitive Examination-III, ACE-R, ACE-III, and foreign language 
translation. Terms were combined using Boolean operators OR and AND. Because the 
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original English language versions of the ACE-R and the ACE-III were published in 
2006 and 2013, respectively, only studies published from 2006 to September 2016 were 
included in the search. Titles and abstracts were first screened for eligibility, with full 
articles accessed for review on the basis of screening. These full text articles were 
reviewed to assess their eligibility in light of the inclusion and exclusion criteria of the 
current review. Reference lists of included studies were reviewed to identify further 
articles. The inclusion criteria were: 1) Studies investigating the diagnostic accuracy of 
non-English versions of the ACE-R and the ACE-III; 2) If more than one study 
translated the ACE-R and the ACE-III to the same language, all studies were included. 
The exclusion criteria were: 1) Studies not in English; 2) Studies on the English 
versions of the ACE-R and the ACE-III; 3) Studies that used non-English versions of 
the ACE-R or the ACE-III to track changes in cognitive functioning over time rather 
than assessing diagnostic accuracy; 4) Studies that used non-English versions of the 
ACE-R or the ACE-III as part of a wider cognitive assessment without providing 
information on diagnostic accuracy; 5) Abstracts, response letters, reviews and guides. 
 
Data Extraction  
Identified abstracts were exported to EndNote and screened against eligibility criteria by 
N.H. Potential articles for inclusion were accessed and reviewed again against eligibility 
criteria, again by N.H. In uncertain cases J.S. was consulted and a decision on 
exclusion/inclusion was reached through discussion. The final list of studies included 
was reviewed by J.S.  
 
Summarising Findings and Quality Appraisal 
Summary data as to aims, participants, study design, analyses, and diagnostic accuracy 
findings was extracted from each included study. Study quality was critically appraised 
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and scored by N.H. using the STARD quality appraisal checklist (Bossuyt et al., 2015). 
STARD was used as it is an international consensus instrument for evaluating the 
diagnostic accuracy of psychometric measures. This consists of 31 items in total with 
items relating to the title (1 item), abstract (1 item), introduction (2 items), methods (17 
items), results (8 items) and discussion (2 items). Each item has a maximum score of 2 
indicating information is present and a minimum of 0 indicating an absence of 
information, with 1 indicating information is present but with inadequate details.  
Scores were summed to give an overall quality score for the study. As recommended by 
the National Institute for Clinical Excellence (NICE, 2014) overall scores were 
combined with an assessment of how likely the issues identified were to alter the 
conclusion of the study to give an overall quality rating of high (++), medium (+), or 
low (-) quality. 
 
Results 
 721 articles were initially identified from the three databases searched. Figure 1 
provides a flowchart summarising the steps taken in excluding and including studies for 
this review. Reasons for exclusion included using the English version of ACE-R or 
ACE-III, using the measure as part of a wider assessment, article not written in English 
or the study focused only on normative data. A total of 16 papers were included in this 
review.  
-Insert Figure 1-  
Summary of Results 
 A summary of study characteristics of all eligible studies is reported in Table 1. The 
studies reported on French, German, Greek, Italian, Japanese, Korean, Mandarin, 
Cantonese, Portuguese and Spanish versions of the ACE-R and a Spanish and Thai 
language version of ACE-III. The mean age (±SD) of participants with dementia in the 
7 
studies ranged between 66.20 (± 8.96) (Konstantinopoulou et al., 2011) and 80.9 (± 3.6) 
(Pigliautile, 2012). Years of education ranged between 3.7 (± 4.2) (Wong et al., 2013) 
and 18 (± 4) (Bastide et al., 2012), male:female ratio varied between 8:8 
(Konstantinopoulou et al., 2011) and 34:92 (Kawata et al., 2012). The types of dementia 
included across the studies were Alzheimer’s Disease, Frontotemporal lobar 
degeneration (FTLD), Behavioural variant frontotemporal lobar degeneration (bvFTD), 
Subcortical vascular dementia.  
- Insert Table 1- 
Information about diagnostic accuracy including cut-off scores, sensitivity, specificity, 
and other ROC analysis metrics only reported values of dementia and normal cognition 
as shown in Table 2. The cut-off scores for the translated measures included in this 
review ranged between 60 (Pigliautile, 2012) and 89 (Bastide et al., 2012). The 
sensitivity of the measures ranged between 82% (Pigliautile, 2012) and 100% 
(Carvalho, Barbosa & Caramelli, 2010 ; Raimondi et al., 2012) and specificity values 
ranged between 68% (Sobreira et al., 2015) and 100% (Pigliautile, 2012; Raimondi et 
al., 2012) Of the 16 studies included in the current review, 12 studies were judged to be 
of low (-) quality, and four were judged to be of medium (+) quality (see Table 2). 
There were some issues general to all or most studies: Across all studies, no information 
was given on how indeterminate scores were handled and the frequency of such scores 
might have inflated or deflated the estimation of the diagnostic accuracy depending on 
whether they occurred more frequently in people with or without dementia (Bossuyt et 
al., 2003). There was also no indication of the time interval between the index and the 
reference tests in 15 studies; consequently, there may have been changes in the target 
condition over time that might have influenced the diagnostic accuracy of the measure 
(Bossuyt et al., 2003). Power calculation and intended sample size was not reported in 
12 studies, despite the importance of determining the sample size needed to identify 
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clinically relevant findings (Machin, Campbell, Fayers & Pinol, 1997). Furthermore, 
nine studies did not include information on the sampling process; thus, it was difficult to 
assess the population to whom the study was generalisable (Knottnerus & Muris, 2002). 
Similarly, in nine studies, assessors were aware of the clinical diagnosis of the 
participants while administrating the ACE-R or the ACE-III. Non-blinding might mean 
that more people were accurately diagnosed in studies than they would be in clinical 
practice because assessors already know who has dementia (Philbrick, Horwitz & 
Feinstein, 1980). Below we discuss each language version individually, where the 
individual studies were rated as low quality it was generally because all or many of the 
above issues were present. Where these issues were (at least partially) addressed and the 
study was of higher quality it is specified in individual language summaries below.  
 
- Insert Table 2-  
 
Results of Individual Studies Categorised by the Language of Translation  
French Translation. A retrospective study investigated the diagnostic accuracy of the 
French version of the ACE-R (Bastide et al., 2012). When differentiating those with 
dementia from healthy controls, the sensitivity of the test was 98.4% and the specificity 
was 98.6%, for a threshold of 89. The findings suggested that the test is a good tool to 
identify people with and without dementia (type not specified). However, the study was 
rated as of low quality due to many of the issues discussed above, and consequently the 
level of bias in the findings is unclear.  
 
German Translation. One study investigated the diagnostic accuracy of a German 
translation of the ACE-R (Alexopoulos et al., 2010). The results of the study suggested 
that the measure could be used to discriminate between people with Alzheimer’s disease 
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(sensitivity = 92%, specificity = 96%) at the threshold of 82 or frontotemporal lobar 
degeneration (sensitivity = 88%, specificity = 96%) at the threshold of 83 from healthy 
controls. However, the study was rated as low quality due to many of the issues 
discussed above, and the ability of the authors to draw an unbiased conclusion about 
sensitivity and specificity may have been compromised.     
 
Greek Translation. The article on the Greek translation of the ACE-R 
(Konstantinopoulou et al., 2011) investigated its diagnostic accuracy in differentiating 
those with dementia of Alzheimer’s type and frontotemporal lobar degeneration from 
those without. The findings from this study suggested that the ACE-R had excellent 
ability to discriminate those with  from those without dementia (sensitivity = 97.1%v 
and specificity = 81.7% at a threshold of 85). However, the study was rated as of low 
quality due to the issues discussed above, possibly biasing conclusions drawn.  
 
Italian Translation. One study evaluated the diagnostic accuracy of the Italian ACE-R 
(Pigliautile, 2012) in young-old adults aged (70.8 ± 3.6) and old-old adults aged (80.9 ± 
3.6) in detecting dementia (type not specified). The findings from the study suggested a 
sensitivity of 90% and a specificity of 80% with a cut-off of 79 for young-old adults and 
a sensitivity of 82% and a specificity of 100% with a cut off of 60 for old-old adults, 
demonstrating good diagnostic accuracy across age groups. However, the study was 
rated as low quality. Consequently, the validity of conclusions as to diagnostic accuracy 
may be compromised.  
 
Japanese Translation. In two studies, the authors investigated the diagnostic accuracy 
of the Japanese translation of the ACE-R in diagnosing dementia (type not specified). 
Both articles Kawata et al., 2012; Yoshida et al., 2012) suggested that the ACE-R is an 
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excellent tool to identify people with dementia (sensitivity = 94%, specificity = 94%) at 
a cut-off of 80 (Kawata et al., 2012) and (sensitivity = 99%, specificity = 99%) at a cut-
off of 82 (Yoshida et al., 2012). In both cases the researchers were blind to clinical 
status of participants, enhancing study validity (Philbrick et al., 1980) but in both cases 
issues such as the lack of clear indication of the time interval between the reference and 
index test means that it is somewhat hard to know to whom the results are generalizable 
and it is notable that different optimal cut-offs were found although there was no 
significant difference in demographics of both studies. Unmeasured differences in the 
samples may account for the different cut offs found here. 
 
Korean Translation. In the article examining the diagnostic accuracy of the Korean 
ACE-R (Kwak, Yang & Kim, 2010). the authors focused on ability both to detect 
dementia and to differentiate between Alzheimer’s disease and Subcortical vascular 
dementia In detecting dementia, test sensitivity was 93% and specificity was 95% at a 
cut-off of 78, suggesting an excellent diagnostic accuracy. However, sensitivity and 
specificity of the test to differentiate between Alzheimer’s disease and Subcortical 
vascular dementia was less accurate. The study was rated as of low quality, perhaps 
compromising ability to draw valid conclusions as to diagnostic accuracy. 
 
Mandarin/Cantonese Translation. One article investigated the diagnostic accuracy of 
the Chinese (Mandarin) translation of the ACE-R (Fang et al., 2014) in diagnosing 
Alzheimer’s disease.  The results suggested that the ACE-R was an excellent tool 
(sensitivity = 92%, specificity = 86%) at a threshold of 67. The study was rated as low 
quality and the validity of conclusions may be compromised due to many of the issues 
discussed above. The second article reported on the diagnostic accuracy of the Chinese 
(Cantonese) translation of the ACE-R (Wong et al., 2013). The results indicated 
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excellent diagnostic accuracy of the ACE-R (sensitivity = 93%, specificity = 95%) in 
diagnosing dementia (type not specified) with cut-off of 73. This study was rated as of 
medium quality, as those administering the ACE-R were blind to diagnostic status and 
there was a specified time interval of a week between index and reference tests. 
Therefore, the validity of the study for drawing a conclusion about sensitivity and 
specificity was probably reasonably high, however lack of clarity regarding sampling 
procedures may affect ability to generalise the results.  
 
Portuguese Translation. The diagnostic accuracy of the Portuguese (Brazilian) 
translation of the ACE-R was assessed in two studies. The findings from the first study 
Carvalho et al.,   2010) suggested 100% sensitivity and 82.26% specificity at a cut-off 
of 78, indicating excellent ability to detect Alzheimer’s disease. The findings from the 
second article on the Brazilian translation of the ACE-R (Sobreira et al., 2015) indicated 
less accuracy in distinguishing between people with or without dementia among those 
who had Parkinson’s disease (sensitivity = 88%, specificity = 68%) at a cut-off of 76. 
However, both studies were rated as low quality. Consequently, while good diagnostic 
accuracy was reported, particularly to detect dementia of Alzheimer’s type, the validity 
of the sensitivity and specificity figures may be compromised.  
In addition to the Brazilian Portuguese versions, one study examined a European 
Portuguese version of the ACE-R study (Gonçalves et al., 2015) and suggested an 
excellent ability to detect those with Alzheimer’s disease (sensitivity = 100%, 
specificity = 97%) and subcortical vascular dementia (sensitivity = 97%, specificity = 
92%) with cut-offs of 72. The study was rated as medium quality because although 
many of the methodological issues affecting other studies were also present here, the 
blinding of the assessors to clinical information when administering ACE-R makes the 
conclusions more robust.   
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Spanish Translation. Two articles were identified on the diagnostic accuracy of the 
Spanish  (Argentinian) translation of the ACE-R, and one article on the Spanish 
(European) translation of the ACE-III. In the first article on the Spanish (Argentinian) 
ACE-R (Raimondi et al., 2012), people who had Alzheimer’s disease or subcortical 
vascular dementia were compared with healthy individuals who participated as study 
controls. The results suggested that the ACE-R is an excellent tool to discriminate 
between people with or without dementia (type not specified) (sensitivity = 100%, 
specificity = 100%) with cut-off of 88. However, the study was rated as low quality. 
Thus the validity of the study to draw a conclusion about sensitivity and specificity may 
have been compromised.  
In the second article, the ability of the Spanish (Argentinian) version of the ACE-R to 
differentiate between Healthy controls and those with dementia (A mixed population of 
Alzheimer’s disease and behavioural variant FTD) was evaluated (Torralva et al., 2011). 
The ACE-R showed excellent sensitivity = 97% and specificity = 88% with a cut-off of 
85. However, due to the issues discussed above the study was rated as of low quality, 
possibly biasing conclusions as to diagnostic accuracy.  
The third article (Matias-Guiu et al., 2015) evaluated diagnostic accuracy of the 
European Spanish translation of the ACE-III the only article in this review examining 
the ACE-III. The results suggested that the ACE-III is a good tool in distinguishing 
those with dementia with a sensitivity of 83%, specificity of  80% with cut-off of 65.6. 
However, the study was rated as of low quality, and ability of the study to draw a 
conclusion about the sensitivity and specificity may have been compromised.  
 
Thai Translation. One study investigated the diagnostic accuracy of the Thai translation 
of ACE-III (Charernboon, Jaisin & Lerthattasilp, 2016). People with early dementia 
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(Alzheimer’s disease, mixed type and vascular dementia) were compared with people 
with mild cognitive impairment and healthy controls. The results revealed excellent 
sensitivity = 100% and specificity = 97% with an optimal cut-off score of 61 to 
differentiate people with and without dementia., The study was rated as of medium 
quality meaning conclusions may be more robust than some other studies reported here. 
 
Discussion 
The aim of the current review was to investigate the diagnostic accuracy of the 
translated versions of the ACE-R and the ACE-III in detecting dementia. In general, the 
translated versions of the ACE-R and ACE-III showed good to excellent sensitivity and 
specificity for detecting dementia. This may vary across subtype as while values were 
high for those with Alzheimer’s disease, FTD and vascular dementia, the one study 
evaluating dementia in Parkinson's indicated poorer diagnostic accuracy. Optimal cut-
off thresholds were less consistent and varied across types of dementia (Torralva et al., 
2011) and also across language versions. This highlights the need to evaluate the ACE-
R/ACE-III in each new population and the need to use ROC analysis to develop cut-offs 
for each new language version and to be clear as to diagnostic subtypes within a sample 
(Borsa, Damasio & Bandeira, 2012). When two studies assessed the same language 
version, optimal cut-offs also varied between studies (Sobreira et al., 2015; Carvalho et 
al., 2010) and (Kawata et al., 2012; Yoshida et al., 2012). While in some cases this may 
be due to methodological problems leading to inter-study variability in sensitivity and 
specificity values (Sobreira et al., 2015; Carvalho et al., 2010) due to bias (Bossuyt et 
al., 2003) this was also the case when both studies were of higher methodological 
quality (Kawata et al., 2012; Yoshida et al., 2012). One possible explanation is that 
unmeasured differences in populations across studies, such as mean age and years of 
education, affect results. The range of the years of education varies between studies. It 
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is possible that without education-adjusted cut-offs to reduce biases (Kittner et al., 
1986) differences between studies are due to educational variation rather than (or as 
well as) cultural variation. These findings also emphasise the need for further research 
on population characteristics other than language, years of education, and age that affect 
ACE-R/ACE-III scores. Premorbid IQ and ethnicity, have been found to be associated 
with other screening tool performance (Whitney, Maoz, Hook, Steiner & Bieliauskas, 
2007; Pedrazaa et al., 2012), and should be measured in relation to ACE-III/ACE-R. It 
should also be noted that while only two studies evaluated the ACE-III, they showed 
very similar results to those of the ACE-R and issues raised in this review in relation to 
the ACE-R will apply equally to the ACE-III. 
 
Methodological Problems and Limitations  
There were some limitations to the review process. Thorough assessment of the identi-
fied articles against inclusion and exclusion criteria was carried out by the first author 
alone. Although the second author was consulted in relation to queries and experts in 
the field were consulted as to any missing articles, this is a limitation. Another limita-
tion was that most studies included in the review were on ACE-R. Similar limitations 
apply to quality assessment of articles. We did not search grey literature as we wanted 
to uphold the quality of included studies, but had we done so we may have identified 
further relevant articles. Additionally, it was a limitation that we did not include studies 
not written in English. This only led to a small number of articles (N=4) relating to di-
agnostic accuracy not being included, but did mean that three languages/cultural vari-
ants of a language (Turkish, Czech and Chilean Spanish) were not included in our re-
view. Another limitation was that we appraised a screening tool that was inherently cul-
turally biased (Dodge et al., 2009) before the process of translation and validation in 
different culture. Additionally, it was a limitation that we only reported the diagnostic 
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accuracy values for dementia without elaborating on mild cognitive impairment in stud-
ies that examined both.   
 
Areas for Future Research and clinical practice 
Given variability in cut-off thresholds found here within and across languages, 
clinicians should be cautious in applying them. Research on specific language versions 
should also be replicated, seeking to evaluate not only the ROC derived optimal cut off 
in their sample but the performance of cut-offs found in previous studies to build up an 
evidence base for specific cut-offs (Grypma et al., 2007) in specific languages. It 
general it is important for future research to adhere to STARD guidelines for diagnostic 
studies in order to reduce bias in conclusions about diagnostic accuracy. Finally, given 
that only two paper examined the ACE-III were eligible for the current review, future 
research could focus on the translated versions of the ACE-III (Hsieh et al., 2013) and 
should consider using established processes for cross cultural adaptation (Hambleton, 
2005) prior to assessment. 
 
Conclusion 
The findings of excellent diagnostic accuracy are compromised by the methodological 
limitations of studies. There is a need for future research to address the limitations 
discussed in the current review through adherence to STARD guidelines. 
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Age in years 
Mean ± SD 
Years of 
Education 
 Mean ± SD 
ACE-R/ACE-III  
Mean ± SD 
French  














18 ± 4 
18 ± 4 
20 ± 4 
70 ± 10 
83 ± 8 















72.00 ± 8.18 
69.64 ± 6.18 
67.83 ± 8.01 
69.64 ± 7.53 
11.02 ± 2.63 
11.70 ± 3.52 
12.00 ± 3.27 
11.78 ± 2.51 
64.80 ± 11.32 
64.50 ± 17.82 
81.34 ± 9.09 
90.37 ± 4.99 
Greek  
(Konstantinopou-










71.69 ± 5.50 
67.47 ± 6.87 
66.20 ± 8.96 
7.75 ± 3.98 
9.89 ± 4.12 
10.60 ± 4.22 
55.63 ± 17.14 
61.00 ± 17.82 
89.13 ± 7.54 
Italian  
(Pigliautile, 2012) 


















70.8 ± 3.6 
69.6 ± 2.8 
 
80.9 ± 3.6 
80.7 ± 3.6 
 
7.1 ± 3.7 
8.9 ± 4.6 
 
7.1 ± 4.8 
7.7 ± 3.9 
 
63.3 ± 13.2 
87.1 ± 9.3 
 
53.6 ± 12.2 
80.5 ± 10.7 
Japanese  








77.3 ± 7.6 
71.5 ±9.1 
10.6 ± 2.5 
12.3 ± 2.6 
58.4 ± 16.4 
90.8 ± 6.9 
Japanese  










75.4 ± 7 
71.4 ± 9.2 
66.3 ± 10 
11.1 ± 2.7 
11.4 ± 2.1 
12.7 ± 2.3 
61.5 ± 12.9 
82.2 ± 6.4 
93.3 ± 3.9 
18 
Korean  
(Kwak et al., 
2010) 
ACE-R AD (n= 30) 






73.1 ± 11.2 
70.1 ± 10.2 
67.8 ± 9.3 
8.9 ± 4.2 
8.6 ± 3.9 
10.1 ± 4.1 
52.5 ± 15.1 
53.2 ± 17.0 
80.7 ± 6.0 
Mandarin (Chi-
nese)  
(Fang et al., 2014) 
ACE-R AD (n= 25) 






73.32 ± 8.13 
69.52 ± 9.69 
68.16 ± 8.18 
9.68 ± 5.01 
10.07 ± 4.41 
11.77 ± 3.46 
55.72 ± 9.20 
76.56 ± 10.31 
87.59 ± 7.68 
Cantonese (Chi-
nese) 










79.2 ± 6.6 
76.9 ± 7.3 
72.8 ± 7.5 
3.7± 4.2 
4.2 ± 4.2 
5.6± 4.3 
50.8 ± 15.4 
68.2 ± 15.7 
86.4 ± 8.9 
Portuguese (Bra-
zilian) 
(Carvalho et al., 
2010) 





78.03 ± 6.74 
77.82 ± 6.58 
9.97 ± 5.19 
10.05 ± 4.98 
63.10 ± 10.22 
83.63 ± 7.90 
Portuguese (Bra-
zilian)  






















(Goncalyes et al., 
2015) 
ACE-R SVD (n= 18) 








75.50 ± 5.29 
75.14 ± 4.12 
76.95 ± 6.92 
 
3.22 ± 1.73 
4.64 ± 3.16 
5.61 ± 2.81 
 
55.06 ± 9.19 
55.53 ± 10.16 
82.11 ± 1.29 
Spanish  
(Raimondi et al., 
2012) 
ACE-R AD (n= 25)  






77.64 ± 5.3 
75.59 ± 6.4 
73.23 ± 8.9 
14.48 ± 3.6 
12.97 ± 4.3 
14.46 ± 2.2 
 
Spanish  
(Torralva et al., 
2011) 








73.4 ± 5.7 
70.0 ± 9.3 
71.5 ±5.6 
12.9 ± 4.6 
12.8 ± 5.1 
13.0 ± 3.8 
78.1 ± 9.4 
64.2 ±16 










77.3 ± 8.4 
71.0 ± 11.0 
7.5 ± 4.6 
9.8 ± 5.9 
50.4 ± 16.0 







MCI (n= 29) 
Healthy (n= 
48) 
 76.9 ± 7.4 
70.7 ± 7.4 
65.6 ± 6.3 
7.7 ± 4.2 
8.6 ± 5.5 
10.5 ± 5.2 
43.5 ± 11.1 
67.8 ± 7.4 
86.1 ± 6.8 
 
 
* Only the median (min-max) was reported in the article. 
A blank space indicates no information is available.  
Abbreviations: Dementia, Dementia type not specified or mixed subtype sample; MCI, Mild cognitive 
impairment; Alzheimer’s, Alzheimer’s disease; FTLD, Frontotemporal lobar degeneration; bvFTD, Be-
havioural Variant Frontotemporal lobar degeneration; SVD, Subcortical vascular dementia, SVD. 
 






















89 98.4 98.6 0.99 32/62 No rational for the cut-off 
point of the reference stand-
ard, non-blinded, indetermi-
nate data was not reported, 
power not calculated, time 
















35/62 Power not calculated, inde-
terminate data was not re-
ported, no rational for the cut-
off point of ACE-R, time 






et al., 2011) 
85 97.1 81.7 0.96 21/62 No rational for the cut-off 
point of ACE-R or the refer-
ence standard, indeterminate 
data was not reported, non-
blind, power not calculated, 















31/62 No rational for the cut-off 
point of ACE-R or the refer-
ence standard, non-blinded, 
indeterminate data was not 

























80 94 94 0.98 37/62 Poorly defined sample, no 
rational for the cut-off point 
of ACE-R or the reference 
standard, indeterminate data 
was not reported, power not 






82 99 99 0.99 44/62 Power not calculated, inde-
terminate data was not re-
ported, no rational for the cut-
off point of ACE-R, time 





78 93 95  35/62 Poorly defined sample, No 
rational for the cut-off point 
of ACE-R or the reference 
standard, indeterminate data 
was not reported, power not 





(Fang et al., 
2014) 
67 92 86 0.95 33/62 Non-blinded, indeterminate 
data was not reported, power 
not calculated, time interval 







73 93 95 0.98 40/62 Indeterminate data was re-
ported, time interval not stat-





et al., 2010) 
78 100 82.26 0.95 31/62 Insufficient details about the 
ACE-R or rational for the 
cut-off point, non-blinded, 
time interval not stated, inde-
terminate data was not re-






76 88 68 0.84 34/62 Non-blinded, power not cal-
culated, indeterminate data 



















34/62 No rational for the cut-off 
point of ACE-R or the refer-
ence standard, poorly defined 
sample, indeterminate data 
was not reported, time inter-




et al., 2012) 
88 100 100 1.0 31/62 Poorly defined sample, no 
rational for the cut-off point 
of ACE-R, non-blinded, inde-
terminate data was not re-


















Main limitations Rating of 
overall 
quality 




85 97 88  32/62 Poorly defined sample, non-
blinded, power not calculat-
ed, indeterminate data was 





Guiu et al., 
2015) 
65.6 83 80 0.92 32/62 No rational for the cut-off 
point of ACE-R or the refer-
ence standard, non-blinded, 
indeterminate data was not 





boon et al., 
2016) 
61 100 97 0.99 42/62 Time interval was not stated, 
poorly defined sample, inde-




* A blank space indicates no information is available.  
**ROC curve; Area under the receiver operating characteristic (AUC) curve, Alzheimer disease 
(AD), Frontotemporal lobar degeneration (FTLD), Subcortical vascular dementia (SVD). 
















Figure Legend: Modified PRISMA flowchart showing search process. 
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